Neuronetics, INC 8-K filings

Neuronetics, Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Neuronetics and Greenbrook TMS have received an interim court order for their proposed merger and have scheduled shareholder meetings for November 8, 2024, to vote on the transaction.

Neuronetics is set to acquire Greenbrook TMS in an all-stock transaction, aiming to create a leading mental health company with expanded reach and capabilities.

Neuronetics is set to acquire Greenbrook TMS, aiming to amplify brand awareness and provide enhanced services to NeuroStar practices.

Neuronetics and Greenbrook TMS are merging to create a larger mental health company, targeting profitability and significant cost synergies by 2025.

Neuronetics Inc. and an investor have entered into a registration rights agreement, granting the investor certain rights to register their shares for resale following the completion of a merger with Greenbrook TMS Inc.

Neuronetics reported a 7% year-over-year revenue decrease in Q2 2024, but announced a definitive agreement to acquire Greenbrook TMS, aiming for a vertically integrated mental health care model.

Neuronetics will acquire Greenbrook TMS in an all-stock transaction, creating a leading mental health provider, while also reporting a 7% decrease in revenue for the second quarter of 2024.

Neuronetics, Inc. has entered into a new debt agreement with Perceptive Advisors, securing up to $90 million to refinance existing debt and support growth initiatives.

Neuronetics presented its financial and operational outlook at the William Blair 44th Annual Growth Stock Conference, emphasizing its Better Me Provider Program, adolescent indication launch, and path to profitability.

Neuronetics, Inc. successfully held its annual meeting, electing all director nominees and ratifying the appointment of KPMG LLP as its independent auditor.

Neuronetics announced a 12% increase in first quarter revenue to $17.4 million, driven by a 22% surge in U.S. treatment session revenue and FDA clearance for adolescent depression treatment.

Neuronetics, Inc. has released its May 2024 investor presentation and supplemental financial and operating information on its website.

Neuronetics, Inc. will reduce its board size from eight to five members following its 2024 annual meeting, with three directors not seeking re-election.

Neuronetics, Inc. announced that it has received FDA clearance for its NeuroStar Advanced Therapy to be used as a first-line, adjunct treatment for major depressive disorder in adolescent patients aged 15-21.

Neuronetics' Board of Directors has approved annual cash incentive compensation awards for its top executives, totaling over $1 million.

Neuronetics reported record fourth-quarter and full-year 2023 financial results, highlighted by a 12% increase in Q4 revenue and positive cash flow.

Neuronetics, Inc. has released its March 2024 investor presentation and supplemental financial information on its website.